Introduction
============

Unlike most tissues in the human body, bone is capable of spontaneous scarless repair throughout adult life. Skeletal tissue heals following injury by producing new bone with structural geometry and biomechanical integrity ([@B114]) indistinguishable from the surrounding bone ([@B3]). The process of fracture healing in the adult skeleton recapitulates embryonic bone development and is considered a form of tissue regeneration ([@B27]). It is a complicated metabolic process, involving certain regenerative patterns and changes in the expression of 1000s of genes ([@B80]). Disruption to this highly coordinated process can result in delayed or impaired healing ([@B122]) leading to mal-union or 'Non-union.' Numerous pre-, intra-, and post-operative factors have been found to be associated with impaired bone healing ([@B92]), including excessive periosteal stripping, damage to surrounding soft tissue, inadequate post-traumatic or post-operative immobilization, repeated manipulations, and excessive early motion at fracture sites ([@B122]). The exact molecular mechanisms of delayed fracture healing, however, are unknown.

Fracture repair is regulated by multiple growth factors ([@B71]). The Wnt signaling pathway has well-known and central roles in bone development, homeostasis, as well as bone repair and regeneration following injury ([@B133]). Wnt ligands stimulate bone growth, suggesting a strong regulatory role for canonical Wnt signaling pathway in bone healing and highlighting its potential as a therapeutic target to augment fracture healing. A number of molecules able to enhance the canonical Wnt signaling have shown promise in pre-clinical and clinical trials ([@B105]).

In this paper we review the canonical Wnt signaling pathway and its role in bone regeneration and repair. A provide an overview of the Wnt pathway and discuss specific canonical Wnt-signaling molecules that may offer favorable targets for facilitating bone repair and regeneration.

Formation of Bone During Embryological Development
==================================================

In the early stages of embryonic development, the skeleton is composed of fibrous membrane and hyaline cartilage ([@B125]). By the sixth or seventh week of embryonic life ossification (osteogenesis), begins ([@B100]). Skeletogenesis involves the combined action of numerous genetic programs governing vasculogenesis ([@B49]), and the specification, proliferation, differentiation, programmed cell death, and remodeling of the ECM. These processes are underpinned by key molecular pivots (Table [1](#T1){ref-type="table"}), and as the molecular orchestra responsible for bone formation in the fetus also plays a role in adult skeletal repair ([@B32]), these pivots represent potential therapeutic targets (Table [2](#T2){ref-type="table"}).

###### 

Key molecules and cells involved in bone repair.

  Key factors                            Function                                                             *In vivo* and *in vitro* effects
  -------------------------------------- -------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Extracellular messengers**                                                                                
  IL-1, IL6, TNFα                        Elicit inflammation and migration                                    *In vitro* inhibit osteoblastic differentiation, but *in vivo* TNFα is crucial for bone repair; role of IL-6 is controversial (anti-or pro-osteogenic probably, depending on soluble IL-6 receptor)
  TGFβ                                   Mitogenic factor, osteogenic factor                                  Can induce osteoblast differentiation at the early stage of immature cells but can also inhibit osteogenesis in committed cells
  BMP2                                   Osteogenic factor                                                    Osteochondrogenic factor; might initiate bone formation and bone healing and can induce expression of other BMPs
  BMP4                                   Osteogenic factor                                                    Osteochondrogenic factor *in vivo* and *in vitro*
  BMP7                                   Osteogenic factor                                                    Osteogenic factor *in vivo* and *in vitro*; active on more mature osteoblasts
  SDF1                                   Chemotactic factor                                                   Allows MSCs homing both *in vitro* and *in vivo*
  Noggin                                 BMP2, 4, and 7 specific inhibitor                                    Suppresses osteoblastic differentiation
  FGFb                                   Angiogenic and mitogenic factor, osteogenic factor (controversial)   Mutations induce chondrodysplasia and craniosynostosis; can stimulate Sox9; might be a negative regulator of postnatal
  IGF-I, II                              Mitogenic factors, osteogenic factors                                Stimulates growth plate formation, endochondrate ossification and bone formation by osteoblasts
  PlGF                                   Angiogenic and vasculogenic factor                                   Induces proliferation and osteogenic differentiation of MSCs; crucial for vascularization
  VEGF                                   Angiogenic and vasculogenic factor                                   Most potent angiogenic and vasculogenic factor; crucial at the onset of bone formation
  PDGF                                   Mitogenic and chemotactic factor                                     Highly mitogenic factor for MSCs and chemotactic for MSCs, osteoblasts and perivascular cells
  Wnts                                   Mitogenic and osteogenic factors                                     Depending on Wnt type, crucial for osteoprogenitor proliferation; can also inhibit final osteoblast maturation
  DKK1                                   Inhibitor of Wnt signaling                                           Strongly inhibits osteogenesis of MSC and osteoprogenitor cells; can stimulate terminal maturation
  Ihh                                    Osteochondrogenic factor                                             Pivotal role for growth plate and endochondral formation; can inhibit osteoblast differentiation; might induce PTHrP expression
  PTHrP                                  Osteochondrogenic factor                                             Pivotal role for growth plate and endochondral formation; can induce or inhibit osteogenesis
  OPG                                    Decoy receptor of RANKL, inhibition of RANKL                         Strongly inhibits bone resorption and has a pivotal role in bone remodeling
  RANKL                                  Induces osteoclastogenesis                                           Strongly stimulates bone resorption and has a pivotal role in bone remodeling
  M-CSF                                  Induces osteoclastogenesis                                           Crucial for osteoclastogenesis
  Gastrointestinal serotonin             Neurotransmitter inhibiting osteogenesis                             Expressed by enterochromatin cells, inhibits bone formation and repressed by Lrp5
  **Intracellular messengers**                                                                                
  PKA/CREB                               Transduce osteogenic signaling                                       Can transduce osteogenic signaling (still controversial); possible indirect effect
  MAPKs                                  Transduce osteogenic signaling by phosphorylation                    Crucial for regulation of intracellular signaling induced by osteogenic factors (still controversial)
  β-Catenin                              Osteogenic transducer factor                                         Pivotal role in transducing osteogenic signal from Wnt and is negatively regulated by GSK3β
  Runx2                                  Early osteogenic transcription factor                                Master regulator of early osteogenesis; runx2 mice died, with no bone formation
  Osterix                                Late osteogenic transcription factor                                 Master regulator of late osteogenesis, inhibiting chondrogenesis
  Dlx5                                   Osteogenic homeobox protein                                          Induces osteoblast maturation but inhibits osteocyte formation
  Msx2                                   Osteogenic homeobox protein                                          Induces proliferation of immature cells; responses depend on Dlx5 quantity
  NF-kB                                  Inflammation transducer factor, inhibits osteogenesis                Inhibits the differentiation of MSCs and committed osteoblastic cells
  **Cells**                                                                                                   
  MSCs                                   Origin of osteoblasts                                                Can form bone *in vivo* and osteoblasts *in vitro*
  Osteoblasts                            Osteogenic professional cells                                        Generate bone formation
  Adipose tissue-derived stromal cells   Multipotential cells                                                 Can give rise to bone *in vivo* and *in vitro* but are less effective than bone marrow MSCsl
                                                                                                              

###### 

Clinical relevance of key factors in bone repair.

  Key factors tested     Observations
  ---------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  BMP2                   Used for spine fusion, bone non-union and bone defects; clinically efficient for bone repair and regeneration; some adverse effects observed (osteolysis and ectopic bone formation)
  BMP7                   Used for spine fusion and bone non-union; clinically efficient for bone repair
  PTHrP/PTH              Used for osteoporosis; efficient for increasing bone mass when intermittently administered
  Wnt-β-catenin          LiCl used as a specific inhibitor of GSK3β to increase bone mass post-fracture and to diminish fracture risk Bortezomib, proteasome inhibitor used in treatment of multiple myeloma (MM); also increases bone mass Anti-DKK1 monoclonal antibody (BHQ880) used to inhibit osteolysis in MM or to increase BMD Anti-sclerostin antibody used to increase bone mass
  RANKL/OPG              Targeting RANKL to treat osteoporosis; e.g., denosumab (anti-RANKL antibody), which can be used with biphosphonates
  Biphosphonates         Widely used for osteoporosis, bone necrosis, osteogenesis imperfecta and some osteolytic tumors (MM) (zoledronate, alendronate, risedronate); some adverse effects noted (osteonecrosis, inhibition of osteogenesis)
  TGFβ                   Used as a bone non-union marker
  Platelet-rich plasma   Used in maxillofacial surgery and for bone defects with or without biomaterials with or without osteoregenerative cells
  MSCs or osteoblasts    *In vitro*-expanded MSCs (or osteoblasts) used for bone defects, osteonecrosis, immune rejection; randomized controlled clinical trials are required
                         

Together, bone and cartilage comprise skeleton, and are produced by osteoblasts and chondrocytes, respectively ([@B98]). During embryological development, bone is formed by (1) intramembranous and (2) endochondral ossification (Figure [1A](#F1){ref-type="fig"}). During embryonic development skeletal elements are separate in places to form joints, critical structures for mobility. Synovial allow for movement between boney fronts, and form upon the dedifferentiation and flattening of chondrogenic cells in newly formed cartilage, which creates an interzone (Figure [1B](#F1){ref-type="fig"}).

![Ways of bone formation. **(A)** Ossification can occur via endochondral or intramembranous mechanisms. As part of the intramembranous ossification, mesenchymal cells differentiate directly into osteoblasts and generate bone tissue. Chondrocytes develop from mesenchymal cell differentiation with forming an intermediate cartilage during endochondral ossification. By mineralizing the matrix, undergoing apoptosis and attracting blood vessels and osteoblasts, hypertrophying chondrocytes that stop proliferating initiate a centric growth plate. **(B)** Histologically detectable flattening and gathering of cells that are forming an interzone, is the first sign of joint formation. This is followed by maturation and remodeling leading to a mature synovial joint. The Wnt signaling pathway is crucial for controlling almost all aspects of this skeleton formation. Osteoblasts (purple); chondrocytes (blue); osteochondroprogenitor cells (brown).](fcell-06-00170-g001){#F1}

Mechanisms of Bone Repair and Regeneration
==========================================

The main function of the skeleton is structural; it creates a strong, protective, mechanically optimal structure for more delicate organs and soft tissues ([@B89]). Bone tissue constantly adapts to biomechanical loading and environmental stress ([@B90]) through two opposing but synergistic processes; bone resorption and bone formation ([@B26]).

Bone repair following damage is a complex and well-organized regenerative process initiated in response to injury which effectively restores skeletal function ([@B86]). Unlike other adult tissues, which generate scar tissue in response to injury, the skeleton undergoes regenerative healing, forming new bone indistinguishable from adjacent, uninjured tissue ([@B20]). Fracture healing mimics early developmental processes and occurs by both direct and indirect repair ([@B105]). Direct (primary) repair is possibly when the bony fronts of adjacent bones are in close contact. This is usually the case after surgical treatment with stable fixation of the injury ([@B94]). Osteoprogenitor cells, osteoclasts, and undifferentiated mesenchymal stem/stromal cells (MSCs) recruited to the fracture site may also promote bone formation in a mechanism similar to formation of bone during intramembranous ossification in the skull and clavicles ([@B130]). During indirect (secondary) healing, bone formation is akin to endochondral ossification, the developmental method by which long bones are originally made in development ([@B74]). Following injury, a soft callus forms composed of largely inflammatory cells. This callus develops into an intermediate cartilaginous template which subsequently undergoes calcification, and ultimately is replaced by woven bone ([@B80]) and then lamellar bone through a remodeling process that takes several months before. The resulting lamellar bone is able to support normal load bearing ([@B80]). With surgical fixation, temporary immobilization, or both, most fractures heal after several months. However, three to 10% of fractures fail to heal and result in the formation of a fibrous or non-union ([@B59]). The rate of successful fracture healing may be increased, and the time of healing decreased, by therapies that induce bone formation at the break point ([@B45]).

Three Wnt Signaling Pathways
----------------------------

Wnt signaling is a pathway that has been conserved over evolution. It regulates important aspects of cell polarity, cell fate determination, cell migration, formation of the primary axis, organogenesis, and the renewal of stem cells during embryonic development ([@B62]). Dysregulation of Wnt signaling has been implicated in many diseases, including autoimmune diseases and cancer ([@B109]).

The name Wnt originates from the fusion of *wingless*, the segment polarity gene of the *Drosophila*, and *integrated* (int-1), the vertebrate homolog ([@B120]). Wnt ligands, which are encoded by 19 Wnt genes, are cysteine rich highly hydrophobic proteins, 320--400 amino acid base pair in length, with an N-terminal signal peptide for secretion, and a high degree of sequence homology ([@B128]). The Wnt ligands bind receptors on the cell surface of recipient cells to activate the Wnt pathway by triggering intracellular signaling cascades which orchestrate numerous cell biological and developmental processes ([@B129]), important in many physiological settings ([@B79]). Due to thier hydrophobic natuextrre, Wnt proteins are found in association with cell membranes and the ECM. They become palmitoylated in the endoplasmic reticulum of Wnt-producing cells in the presence of acyltransferase porcupine ([@B44]). This palmitate modification is thought to assist in ligand reception on Wnt-responding cells ([@B83]). Modified Wnt proteins are then transported and secreted in secretory vesicles which are under control by Wntless/Evi (evenness interrupted) -- the multi-pass transmembrane protein present in the plasma membrane and/or the Golgi apparatus ([@B18]). This facilitates the release of Wnt protein from the cells and thus their association with the seven-pass transmembrane receptor Frizzled (Fzd) ([@B81]). Fzd is present on the surface of responding cells and possesses a large extracellular domain, the 'cysteine-rich domain' -- made of 10 cysteine residues in a conserved motif'([@B47]). Low-density lipoprotein receptor-related proteins 5 or 6 (LRP5/6) or ROR act as co-receptors to Fzd and assist the binding between Wnt proteins and the receptor ([@B78]). The co-receptor engaged then determines the downstream effect of the successful ligand binding, initiating either the non-canonical or the canonical pathways ([@B85]). As the Wnt signaling pathway is fundamental during embryological development, the expression of Wnt proteins and antagonists happens under strict temporal and spatial regulation ([@B62]).

Intracellular Wnt signaling is categorized into least three main pathways: (1) the β-catenin dependent pathway (also called the 'canonical Wnt pathway'); (2) the planar cell polarity (PCP) pathway; and 3. the Wnt/Ca^2+^ pathway ([@B46]). In the canonical Wnt signaling pathway, the ubiquitination and degradation of β-catenin mediated by glycogen synthase kinase 3 (GSK-3) is inhibited ([@B33]). In the PCP pathway, Wnt signaling activates jun N-terminal kinase (JNK) and this results in cytoskeletal rearrangements into an asymmetrical organization, as well as polarization of cell morphology within the plane of epithelial sheets ([@B34]). This pathway shares many components of the canonical Wnt pathway including Frizzled, and the downstream components GTPase Rho and a kinase cascade including Misshapen, JNK kinase, and JNK ([@B42]). GSK-3 and adenomatous polymosis coli (APC) of the canonical Wnt signaling pathway are also involved in spindle orientation and asymmetric cell division of *C. elegans* and *Drosophila* ([@B131]). In the Wnt/Ca^2+^ pathway, Wnt is involved in the release of intracellular calcium, possibly via G proteins ([@B75]; [@B116]). This pathway includes activation of Phospholipase C (PLC), protein kinase C (PKC), and calmodulin-dependent kinase II, and has a role in *Xenopus* ventralization and in the regulation of convergent extension movements ([@B56]). The canonical Wnt signaling pathway is the best characterized and is strongly implicated in skeletal tissue regeneration and repair ([@B19]) (Figure [2](#F2){ref-type="fig"}).

![The Wnt signaling cascades. **(A)** The canonical Wnt signaling cascade depends on β-catenin, which serves as an intracellular signaling molecule. In case Wnt is not binding to Fz receptors, β-catenin is sequestered into a destruction complex composed of Axin, CK1α, APC and GSK3β, phosphorylated, ubiquitinylated and subsequently degraded by the proteasome. Following the binding of Wnt to Fz receptors and LRP5/6 co-receptors, DSH recruits the destruction complex to the cell membrane by interacting with the receptor complex. This allows newly synthesized β-catenin to accumulate within the cytoplasm and to translocate to the nucleus. By displacing the transcriptional co-repressor groucho from TCF transcription factors, nuclear β-catenin can activate a gene transcription program, whereas Wnt-binding antagonists (sFRPs/WIF) and Wnt receptor antagonists (Dkk/SOST) inhibit the canonical cascade. **(B)** The non-canonical Wnt signaling cascade is characterized by the activation through phosphorylation cascades, which are themselves activated by specific ligand--receptor interactions, seemingly without engagement of the LRP co-receptors. Increasing intracellular Ca^2+^ levels following PLC- and DAG production can trigger many of these cascades. Subsequently, PKC and CaMKII can activate transcription factors like NFκB and CREB, mediated IP3 and calmodulin is involved in the activation of NFAT. However, only the Wnt-binding antagonists are able to inhibit the non-canonical cascade. APC, adenomatous polyposis coli; CaMKII, calcium/calmodulin-dependent protein kinase type II; CK1α, caseine kinase 1-α; CREB, cyclic AMP-responsive element-binding protein; DAG, diacylglycerol; Dkk, Dickkopf; DSH, disheveled; GSK3β, glycogen synthase kinase-3 β; IP3, inositol 1,4,5-triphosphate; LRP, low-density lipoprotein receptor-related protein; NFAT, nuclear factor of activated T cells; NFκB, nuclear factor κB; PIP2, phosphatidylinositol 4,5-bisphosphate; PKC, protein kinase C; PLC, phospholipase C; sFRPs, secreted frizzled-related proteins; SOST, sclerostin; WIF, Wnt inhibitory factor.](fcell-06-00170-g002){#F2}

Canonical Wnt Signaling Pathway
===============================

Recent investigation into the canonical Wnt pathway has led to novel insights into the various levels of canonical Wnt signaling whichhave refined the model of how this pathway is regulated ([@B135]). At least seven of 19 Wnt proteins (Wnts 1, 2, 3a, 3b, 4, 8, and 10b), can activate this pathway ([@B15]). Cannonical Wnt signaling results in the accumulation and translocation of Beta-catenin (β-catenin), into the nucleus ([@B25]). β-catenin is an adherens junction-associated protein and functions to: (1) enable cell--cell adhesion; and (2) mediate intracellular Wnt signaling ([@B119]). Intranuclear accumulation of β-catenin activates transcription factors that target specific genes that mediate cellular development ([@B11]). Dysregulation of β-catenin signaling is implicated in a number of malignancies, suggesting its important role in the control of cellular proliferation and/or cell death ([@B115]). In the absence of Wnt ligands, cytoplasmic β-catenin is degraded by a multiprotein complex made of Axin, casein kinase 1 (CK1), APC and GSK3 ([@B111]). CK1 and GSK3 phosphorylate β-catenin in the NH2-terminal degradation box, targeting it for ubiquitination ([@B111]). bTRCP1 (a component of ubiquitin E3 ligase) or bTRCP2 complex the ubiquinate phosphorylated β-catenin for proteasome-mediated degradation by the β-catenin destruction complex ([@B99]).

The canonical Wnt pathway is activated by binding of specific Wnt ligands to the Fzs along with the LRP-5/6 co-receptors ([@B33]). However, Wnt intracellular signaling is complex ([@B106]); there are 10 known human Fz receptors to date ([@B108]), and although the role of Fz in acting as a receptor for Wnts has long been known, the role of LRP-5 and its homolog LRP-6, acting as co-receptors for Wnt proteins has only recently been established ([@B78]). The Dickkopf (Dkk) family are secreted proteins which bind LRP-5 or LRP-6 with high affinity can therefore directly antagonize canonical Wnt binding ([@B78]). Upon the successful binding of Wnt with its receptors, the intracellular protein, Dvl, is activated. Dvl transduces the membrane signal from the receptor complex ([@B40]) by inhibiting GSK-3b, leading to the collapse of the multi-protein β-catenin destruction complex ([@B82]). Consequently, β-catenin is not phosphorylated and targeted for proteasome mediated degradation and is able to accumulate in the cytoplasm and translocate to the nucleus. Intranuclear β-catenin then associates with members of the T cell factor/lymphoid enhancer factor (TCF/LEF) family and together they activate the transcription of numerous genes involved in a range of functions, for example c-myc and cyclin D1 ([@B77]).

The first indication of a link between bone biology and canonical Wnt signaling was discovered more than one decade ago ([@B6]). Mutations in the Wnt signaling cascade were found to result in excessive bone growth or in excessive resorption ([@B134]): loss of function mutations of the co-receptor LRP5 causes syndromes characterized by low bone mass and consequently frequent bone fractures ([@B96]); alternatively, the gain of function mutations of LRP5 receptor lead to high bone mass ([@B4]). These findings are further corroborated by the association of SNPs of the LRP5 gene with reduced bone mineral density (BMD) and an elevated risk of osteoporotic fractures ([@B104]). LRP5 and LRP6 also transduce Wnt signaling *in vitro* and indicated overlapping roles during *in vivo* skeletal patterning ([@B22]). Although LRP5/6 regulate bone mass, the mechanism by which they do so is yet to be fully elucidated.

Recent research shows that that gene variation in Wnt-16 has also been linked with decreased BMD and osteoporotic fractures; Wnt-16 knockout mice have a substantial decrease in bone thickness ([@B141]). The initial phase of skeletal tissue repair or active bone remodeling is similar to that occurring during skeletal embryogenesis as skeletal stem cells are shuttled to either the osteogenic or the chondrogenic route ([@B9]). One study reporting on the Wnt involvement in fracture repair identified upregulation of Wnt5A, β-catenin, FZD, and numerous target genes following injury ([@B61]). A later follow-up study demonstrated upregulation of additional Wnt related markers such as Wnt5B, LRP5, Disheveled (Dvl), TCF1 and peroxisome proliferator-activated receptor delta (PPARD) ([@B112]). In contrast, the transcription factor LEF1 was repressed during the initial phases of bone repair, and the stage at which maximal bone was formed ([@B107]). However, LEF1 inhibits RUNX2-dependent activation of OCN in osteoblasts. RUNX2 is the transcription factor needed for development of the osteoblast. This suggests that decreased LEF1 expression is necessary for bone repair to occur ([@B97]). As described above, β-catenin has various roles at different stages of bone repair. In the early phases following injury, β-catenin regulates the ratio of osteoblasts and chondrocytes present in the callus which arises from pluripotent MSCs ([@B5]). Later in the bone healing process, β-catenin induces differentiation of osteoblasts and osteoblastic matrix production ([@B126]). LRP5 and β-catenin gene expression is upregulated in cells present in the fracture callus. β-catenin is also expressed in proliferating periosteal osteoprogenitor cells, chondrocytes, as well as osteoblasts, which suggests the canonical Wnt signaling pathway is active in both endochondral and intramembranous ossification ([@B61]; [@B72]; [@B98]). Recent work has corroborated this hypothesis; fractured long bones of LRP5 knockout mice are reduced in size, have decreased BMD, and are biomechanically inferior to the long bones of wild-type (WT) littermates ([@B61]). Furthermore, administration of the Wnt antagonist, DKK1 antibody increased the size of the fractured tissue, as well as its BMD and biomechanical properties. This illustrates how ablation of the Wnt-LRP5 interaction delays the reestablishment of biomechanical integrity during bone repair, and that the canonical Wnt pathway, and specifically the LRP5 coreceptor, are key components of fracture repair.

The non-canonical Wnt pathways also contribute to intramembraneous and endochondral ossification following fracture ([@B43]). Wnt-5a is a non-canonical Wnt ligand and has been found to play an integral role in BMP2-mediated osteogenic differentiation ([@B87]). During osteogenic differentiation, BMPs act to downregulate Wnt signaling via sclerostin and Dkk-1 ([@B53]; [@B140]). Absence of the BMP receptor type 1 in osteoblasts of mice results in decreased levels sclerostin and Dkk-1 and increased bone mass ([@B53]). The Wnt-antagonizing effects of BMP led to the suggestion that Smad1 forms a complex with, and thus sequesters, Dvl ([@B73]). However, understanding the balanced interplay between the BMPs and Wnt ligands are still under intense investigation.

Activation of the Notch pathway inhibits Wnt/β-catenin-induced osteogenic differentiation ([@B12]). Overexpression of the Notch intracellular domain, both *in vivo* and *in vitro*, is associated with reduced Wnt signaling and impaired osteoblastogenesi ([@B72]). The Hedgehog (Hh) works upstream of the Wnt pathway sequentially and promote the osteogenic differentiation of MSCs ([@B52]), and is thus proposed to regulate the early stages of osteogenic differentiation of MSCs ([@B8]). Inhibition of Wnt signaling reduces Hh-induced osteogenic activity in both *in vitro* and *in vivo* models ([@B48]).

Wnt signaling is also involved in osteoimmunomodulatory pathways. Of note, tumor necrosis factor (TNF)-α promotes the activity Dkk-1 and thus block osteoblast differentiation ([@B24]). Mice overexpressing TNFα have a rheumatoid arthritis-like destruction of their joints ([@B7]). Antibody mediated Dkk-1 neutralization in the TNFα transgenic mice rescues the joint destruction and even results in the formation of osteophytes ([@B24]). The balance between skeletal bone formation and resorption and the interaction between the Wnt pathway and TNFα-induced inflammatory process, is complex.

There is increasing evidence of crosstalk between the Wnt pathway and other signaling pathways. For example, Wnt pathways reciprocally regulate the progranulin growth factor in frontotemporal dementia ([@B102]). Progranulin, or 'proepithelin,' is a newly identified growth factors able to promote the differentiation of MSCs into chondrocytes as well as endochondral ossification ([@B132]). The interplay between Wnts and progranulin in osteogenesis are a subject of future investigations.

Wnt signaling found to induce osteogenic differentiation via changing MicroRNA (miRNA) ([@B64]). A number of different miRNA molecules can promote or inhibit MSC mediated osteogenic differentiation ([@B54]). miRNA function to interact with several growth factors and transcriptional factors such as Runx2 and osterix, at various stages of osteogenic differentiation ([@B123]). Several miRNAs specifically interact with Wnt ligands, with a consequent effect on osteogenesis ([@B93]); miR-27 inhibits APC, and thus canonical Wnt signaling and promotes bone formation ([@B127]), and miR-335-5p downregulates Dkk-1 and thus promotes osteogenic differentiation ([@B136]).

Mesenchymal Stem/Stromal Cells (MSCs) and Wnt Signaling in Bone Development and Homeostasis
===========================================================================================

Mesenchymal stem/stromal cells are multipotent progenitor cells with that ability to into multiple tissue types, including bone, cartilage, fat, tendon, and muscle ([@B58]). MSC fate and self-renewing potential, transient amplifying activity is under the influence of the MSC microenvironment and systemic factors ([@B21]). MSCs populate various anatomical locations including the bone marrow and fat, and their impressive differentiation capacity makes them a favorable therapeutic option ([@B14]). The ability to promote osteogenic differentiation of MSCs, either prior or post-transplantation, may serve as an effective therapy to promote bone formation in areas of deficiency ([@B124]). In the 1960s and 1970s, [@B31] were first to describe the rare population (∼0.0001%) of nucleated cells in the bone marrow which adhere to plastic, form cells of spindle-shaped morphology, and rise to round-shaped fibroblastoid colonies (colony-forming unit-fibroblasts or 'CFU-Fs'). [@B29] also demonstrated that the bone marrow derived cells have the capacity to differentiate into bone, cartilage, and/or adipose tissue upon *in vivo* transplantation.

The commitment of MSCs down a certain cell lineage is under the control of a collection of growth factors, but current understanding of the processes influencing cell fates is limited ([@B68]). Studies in both mice and humans show that MSCs can augment bone regeneration by differentiating into osteoblasts as well as by secreting osteogenic growth factors and anti-inflammatory cytokines ([@B144]). [@B41] transduced MSCs to express firefly luciferase and show that MSCs migrate toward the fracture site via the CXCR4 receptor and then promote healing by increasing the cartilage and bone content of the callus, thus altering its biomechanical properties. A clinical study reported on the bone-healing effects of MSCs when used as treatment of defects of long bones, with beneficial effects still evident 7-years later ([@B38]). Another clinical study demonstrated the beneficial effects on injecting MSCs along with bisphosphonates to treat femoral head core decompression and avascular necrosis ([@B36]). Injection of an antagonists against the chemokine CC receptor (CCR1) reveals that this receptors is an important chemoreceptor directing MSC migration and osteoblastic differentiation ([@B37]). Osteoporosis is a systemic bone disease largely affecting the elderly population. Glucocorticoid-induced osteoporosis in rats can be prevented through systemic administration of allogenic MSCs via their osteoblastogenic effects. Together these data suggest MSCs undergo osteoblastic differentiation and promote a more regenerative inflammatory state, and this may have therapeutic implications for a number of diseases of the bone ([@B91]).

Wnt signaling pathway has a well-established critical role in promoting osteogenic differentiation of MSCs ([@B70]). Additionally, Wnt ligands stimulate osteoblast proliferation and support osteoblast maturation (Figure [3](#F3){ref-type="fig"}). The Wnt signaling pathway is involved in both intramembranous and endochondral ossification ([@B142]). [@B84] used a mouse model to demonstrate that enhanced Wnt signaling through the delivery of liposomal vesicles containing purified Wnt-3a protein resulted in accelerated fracture healing due to increased proliferation and earlier differentiation of skeletal stem cells/progenitor cells. This highlights the therapeutic potential of using a biochemical strategy through which proteins can be used to deliver Wnt ligands, and thus to increase the duration and strength of the bone healing effect of Wnt signaling. Previously it has been shown that β-catenin can promote the progression of MSCs from osteoblastic precursor cells into more mature osteoblasts and can also suppress the differentiation of MSCs into adipogenic and chondrogenic lineages ([@B13]; [@B118]). The canonical Wnt pathway is especially influential in inhibiting the expression of the major adipogenic inducers, PPARγ and CCAAT/enhancer binding protein α, to suppress adipogenic differentiation while upregulating the osteogenic regulators Runx2, Dlx5, and Osterix ([@B55]). In addition, non-canonical Wnt signaling also induces osteogenic differentiation through a different mechanism ([@B2]). The non-canonical ligand Wnt-5a suppresses PPARγ ([@B117]) and thus inactivates chromatins. Although the interplay between these two independent mechanisms induced by Wnt ligands is still not totally understood, it is evident that Wnt signaling regulates the osteogenic differentiation of MSCs ([@B138]).

![Role of Wnt signaling in osteoblasts. **(A)** Upon binding to its receptor (Frizzled) and co-receptors (LRP5 and LRP6), Wnt activates their signaling pathway, leading to gene expression (and ultimately protein synthesis and the formation of bone). **(B)** Wnt antagonists sclerostin and Dkk-1 bind LRP5 and LRP6, preventing their interaction with Frizzled and resulting in inhibition of gene expression. **(C)** Loss-of-function mutation in a gene that encodes for a Wnt antagonist orpharmacological engagement of the antagonist with an inhibitory molecule such as an antibody can lead to inhibition of Wnt antagonism and promote gene expression.](fcell-06-00170-g003){#F3}

Bone morphogenic proteins (BMPs), mainly BMPs 2, 6, and 9, are potent growth factors which stimulate MSCs to undergo differentiation into osteocytes ([@B103]). There is substantial crosstalk between BMP and Wnt signaling ([@B72]); different BMPs either enhance or antagonize Wnt-induced osteogenic differentiation ([@B51]; [@B130]), BMP-induced osteogenic differentiation of MSCs is dependent upon functional Wnt signaling ([@B113]), and the Wnt and BMP pathways share common targets, such as the connective growth tissue factor ([@B76]; [@B110]). The osteogenic effects of BMP9 are enhanced by Wnt-3a and inhibited by β-catenin knockdown or overexpression of FrzB, which is a Fzd antagonist ([@B10]). The ability of BMP2 to induce ectopic bone formation is antagonized by Dkk-1 overexpression or conditional knockout of β-catenin ([@B17]). BMP2 is thought to promote osteogenic differentiation by increasing the expression of LRP5 and stabilizing β-catenin through the downregulation of β-Trcp ([@B137]).

Overall, the Wnt and additional signaling pathways interact in an extensive network during osteogenic differentiation regulated by a variety of molecules. Full characterization of all these interactions is yet to be completed. Nevertheless, a better understanding of the intricate trans-pathway crosstalk in osteogenesis is a necessity in order to develop new therapies able to act on these signaling pathways for clinical benefit.

Opportunities for Therapeutic Use
=================================

The ability to control the self-renewal, proliferation, and differentiation of skeletal stem cells could lead to the possibility of expanding a small population of adult progenitor cells and inducing their differentiation in a time sensitive manner to replenish the function of skeletal and cartilaginous tissue ([@B60]). Bone regeneration for fracture repair and defect healing has been a focus of orthopedic surgery ([@B3]). Internal and external fixation at orthotopic sites is the standard of care and achieves short-term stabilization, however, successful long-term stability still requires bone fusion or bone augmentation ([@B35]). Autogenous bone grafting is a common technique to repair large-sized skeletal defects ([@B88]), but donor bone is limited in supply and harvesting can cause significant morbidity at the donor site. Additionally transplanted grafts are at risk of infection and failure. Allograft bone may be antigenic and comes with the risk of transmitting disease ([@B50]), and biomaterials increase the rate of infection and often have suboptimal biomechanical properties ([@B1]). A cost-effective pharmacologic agent that can be delivered non-invasively is the ideal therapeutic way to promote bone repair and regeneration ([@B139]). Factors BMP-7 (or 'osteogenic protein 1,' OP-1) and BMP-2 have been used with increasing success in preclinical and clinical trials ([@B101]). Supplementation with these BMPs enhances bone formation, however, they are effective only in excessive quantities and have short half-lives and thus short-term bioavailability. Additionally, there are currently no methods currently able to deliver these proteins allowing their sustained release, and this has hindered progress to the use of BMPs in humans ([@B16]).

The Wnt pathway is well-characterized and is thus an attractive therapeutic for bone repair and skeletal homeostasis ([@B65]; [@B39]). Additionally, a substantial body of literature has accumulated supporting the role of Wnt signaling in skeletogenesis and the regulatory functions of Wnt signaling on stem and skeletal cells ([@B69]). Animal models of osteoarthritis have implicated Wnt/β-catenin signaling abnormalities in the changes observed in the cartilage and the bone, and this suggests that the β-catenin pathway may be a therapeutic target for osteoarthritis ([@B57]). Sclerostin, a SOST gene product expressed by articular chondrocytes and osteocytes, and inhibits Wnt signaling ([@B67]). Sclerosteosis and van Buchem disease are rare genetic disorders with low levels of sclerostin and high BMD. Research in animals suggests that sclerostin may be a potential target for the treatment of conditions of characterized by low BMD and increased risk of fractures, such as osteoporosis ([@B63]; [@B95]), and sclerostin is being investigated as a treatment for post-menopausal osteoporosis ([@B66]). Production of highly specific antibodies to inhibit a ligand or receptor may help to develop effective therapies that are affordable and can thus become widely used products Humanized sclerostin monoclonal antibodies currently being developed include Romosozumab (AMG 785, CDP-7851; co-developed by Amgen, Thousand Oaks, CA, United States, and UCB, Belgium) and Blosozumab (Eli Lilly and Company, Indianapolis, IN, United States). BPS804 (Novartis, Basel, Switzerland), an antisclerostin agent. The interactions between Wnt receptors and co-receptors also represent reasonable therapeutic targets ([@B78]). Dual inhibition of Wnt via the antagonist DKK-1 in animals treated with sclerostin antibody, results in synergistic bone formation in rodents and non-human primates, suggesting that a negative feedback mechanism limits Wnt-driven bone formation ([@B28]).

Although there are multiple potential benefits of manipulating the Wnt signaling cascade, these should be performed with caution. The Wnt signaling cascade regulates numerous pathological processes, including the development of cancer ([@B121]). The transportation of Wnt proteins to the target is still challenging, since they are hydrophobic and therefore insoluble in aqueous substances. However, Wnt has successfully been purified and packaged into liposomes, circumventing this delivery challenge ([@B84]). Incubation of L-Wnt3a can further enhance the survival, proliferation, and engraftment efficiency of bone marrow cells, partly by blocking caspase-dependent programmed cell death ([@B23]). Besides, other molecules intervening on different components of the canonical Wnt signaling pathway may offer therapeutic potential ([@B124]; [@B143]). One of these is Lithium, which inhibits GSK3 and can thereby increase β-catenin, with promising effects on bone healing ([@B30]). Further investigation may reveal additional molecules able to potentiate the bone-healing effects of the Wnt signaling pathway.

Conclusion and Future Directions
================================

Wnt signaling during bone regeneration and repair involves a well-organized interaction among various cells and regulatory factors. The ability of adult bone to scarlessly regenerate can be impaired resulting in pathological fractures that become fibrous or fail to unite. The therapeutics developed to promote bone regeneration have focused on stimulating MSCs and their osteogenic differentiation. It is increasingly apparent that Wnt signaling plays a fundamental role during the embryological development of bone and cartilage and, in the adult skeleton, regulates bone homeostasis, repair, and regeneration. The Wnt pathways influence stem cell proliferation, differentiation, and maintenance. Mutations in Wnt genes, receptors, and inhibitors can have detrimental effects on bone formation and turnover, and can result in skeletal abnormalities. Recent progress in understanding the critical roles of Wnt/β-catenin signaling in the development and maturation of skeletal cells has invited opportunities to develop pharmaceutical agents to treat non-unions and accelerate fracture repair. Despite the rapid and measurable accomplishments, the role of the Wnts and Wnt antagonists on skeletal physiology and regeneration remain to be fully elucidated. Clinical trials are currently being undertaken to explore the effects of therapeutic agents manipulating the Wnt signaling pathway on a number of endocrine and orthopedic conditions.
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